Abstract
Novel oral anticoagulants (NOACs) are used in patients undergoing direct-current cardioversion (DCCV) for atrial fibrillation and atrial flutter (AF/AFL). There are concerns about their efficacy and safety in severely obese patients as volume of distribution is related to weight and few such
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
